Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE: Transition from Cangrelor to Oral Antiplatelets in CAD
NCT01979445Phase 2Completed
- Sponsor
- The Medicines Company
- Start
- Dec 2013
- Primary completion
- Jan 2014
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of cangrelor in coronary artery disease (CAD), sponsored by The Medicines Company. Started Dec 2013; status: completed.
02
Drugs
cangrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01979445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01979445.